The identification of PTPN11 mutations in KMT2A-rearranged leukemia and the requirement for SHP2 function in the RAS signaling pathway strongly suggest that small molecule SHP2 inhibitors might have important therapeutic applications. The gene discussed is PTPN11; the disease is leukemia.